预约演示
New phase 2 study launched to evaluate triple drug combination in pancreatic cancer
2024-06-25
临床2期免疫疗法疫苗
The University of Glasgow and the NHS Greater Glasgow and Clyde have launched a mid-stage study to evaluate a new drug combination as a first-line treatment for patients living with metastatic pancreatic cancer.
As pUniversity of GlasgowPanc Platform, the phase 2 PRIMUS-006 study will evaluate Eli Lilly and Genentech’s Gemzar (gemcitabine) in combination with Merck & Co’s – known as MSD outsmetastatic pancreatic cancerruda (pembrolizumab) and Immodulon Therapeutics’ investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).
Currently the tenth most common cancer in the UK, pancreatic cancer is responsible Eli Lillythan Genentechw cGemzar (gemcitabine)Merck & CoKeytrudapembrolizumabImmodulon TherapeuticsIMM-101metastatic pancreatic ductal adenocarcinoma (PDAC)
Often fatal, PDAC is commonly focancero late and dpancreatic cancerell to treatments.
Co-ordinated PDAChe Glasgow Oncology Clinical Trials Unit, the new combination therapy will be evaluated in up to 50 patients diagnosed with metastatic PDAC who may not be able to receive current combination chemotherapy from up to 20 hospital sites in the UK.
The chemotherapy drug Gemzar is indicated as a first-line treatment for a variety of cancers, including bladder, breast, pancreas, ovary and metastatic PDAClung cancer, while Merck’s T-cell checkpoint inhibitor is used in cancer immunotherapy for multiple cancers, including melanoma, lung cancer, cervical cancer and certain types of breast cancer.
Immodulon’s investigatGemzarIMM-101 is an immunomodulatory drug containing heat-killecancerse-cell Mycobacterium obuense, which is currently being evaluated in chemotherapy.Merckinhibitorcancercancersmelanomalung cancercervical cancerbreast cancer
Immodulon David Chang, chiefIMM-101igator and professor, surgical oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow and Glasgow Royal Infirmary, commented: “The… PRIMUS-006 study is an important milestone in the pursuit to develop new treatment options to improve the overall outcomes in patients diagnosed with pancreatic cancer.”
Most recently, Merck’s Keytruda received approval from the US Food and Drug AdministratioCancerombination with caUniversity of Glasgowxel, Glasgow Royal Infirmaryent, to treat adults with primary, advanced or recurrent endometrial carcinoma.pancreatic cancer
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。